Crosslinked Organogels for Drug Delivery

Patent metadata

Field	Value
Publication number	US-2025262306-A1
Application number	US-202318857403-A
Country	US
Kind code	A1
Filing date	Apr 18, 2023
Priority date	Apr 18, 2022
Publication date	Aug 21, 2025
Grant date	—

Abstract

This disclosure relates to use of tough organogels in drug delivery. Specifically, this disclosure relates to use of crosslinked elastomer organogels and organogles of polyurethanes modified with one or more lipophilic groups in drug delivery.

First claim

1 . An organogel comprising: a polymer component, an organic solvent, and at least one therapeutic agent or diagnostic agent dispersed within the polymer component, wherein the polymer component comprising-comprises 1) one or more of crosslinked elastomers, or 2) one or more modified polyurethanes, wherein each polyurethane comprises one or more lipophilic groups attached to the polyurethane, optionally through a linker, at a carbamate moiety of the polyurethane.

2 . The organogel of claim 1 , wherein the organogel comprises at least one therapeutic agent that is a hydrophobic small molecule drug selected from group consisting of an anti-cancer agent, an antibiotic, an antiviral, an antiparasitic agent, an anti-inflammatory, an anticoagulant, an analgesic agent, an anesthetic agent, and any combination thereof, or wherein the organogel comprises at least one diagnostic agent that is a hydrophobic small molecule.

3 . (canceled)

4 . The organogel of claim 2 , wherein the at least one therapeutic agent or diagnostic agent is present in the range of about 5 to 50 wt % based on the weight of the organogel.

5 - 6 . (canceled)

7 . The organogel of claim 1 , wherein the organogel comprises one or more of crosslinked elastomers as the polymer component and at least one hydrophobic small molecule drug.

8 . The organogel of claim 7 , wherein the one or more of crosslinked elastomers is vulcanized natural rubber.

9 - 11 . (canceled)

12 . The organogel of claim 1 , wherein the organogel comprises one or more of modified polyurethanes as the polymer component and at least one hydrophobic small molecule drug.

13 . The organogel of claim 12 , wherein the modified polyurethane is a hydrophilic polyurethane.

14 . The organogel of claim 13 , wherein the hydrophilic polyurethane is an ether-based hydrophilic polyurethane, or is a hydrophilic thermoplastic polyurethane elastomer.

15 . (canceled)

16 . The organogel of claim 12 , wherein the polyurethane is an amphiphilic polyurethane.

17 . The organogel of claim 12 , wherein the polyurethane is a hydrophobic polyurethane.

18 . The organogel of claim 12 , wherein the polyurethane is a block copolymer that contains urethane linkage.

19 . (canceled)

20 . The organogel of any of claim 12 , wherein the one or more lipophilic groups on the modified polyurethane comprises lauryl, palmityl (cetyl), myristyl, stearyl, oleyl, lauroyl, palmitoyl (cetoyl), myristoyl, stearoyl, or oleoyl, or a cholyl, deoxycholyl, or lithocholyl moiety.

21 . (canceled)

22 . The organogel of claim 12 , wherein the linker on the modified polyurethane is derived from diisocyanates, diisothiocyanates, or sulfonyl chlorides and/or is of the formula:

where X is —O—, —S—, or —NH—.

23 . (canceled)

24 . The organogel of claim 12 , wherein the linker on the modified polyurethane is configured to attach one lipophilic group or is configured to attach to 1 to 10000 lipophilic groups.

25 . (canceled)

26 . The organogel of claim 12 , wherein the modified polyurethane has a Mw of 500 Da to 50 kDa.

27 . The organogel of claim 1 , wherein the organic solvent is present in an amount of at least about 10 wt %, or at least about 25 wt %, or at least about 50 wt %, based on total weight of the organogel, and wherein the organic solvent is a synthetic oil or natural oil.

28 - 30 . (canceled)

31 . The organogel of claim 1 , having
(a) a young's modulus values of at least 0.25 MPa, of at least 0.5 MPa, of at least 1 MPa, of at least 2 MPa, of at least 2.5 MPa, or at least 4 MPa, or at least 5 MPa, or at least 10 MPa, as determined by ASTM F2258 tensile test; (b) interfacial toughness of at least 100 J m −2 , or at least 150 J m −2 , or at least 200 J m −2 , or at least 500 J m −2 , or in the range of 700 to 1500 J m −2 , in fully swollen state as determined by ASTM D 2861 standard 90-degree peeling test; (c) rupture stretch value (2) in the range of 2 to 25, or 2 to 15, or 2 to 10, or 4 to 25, or 4 to 15, or 4 to 10, or 5 to 8, as determined by ASTM F2258 tensile test; and/or (d) fracture toughness in the range of 2 to 20 KJ/m 2 , as determined by ASTM E1820 tensile test.

32 - 36 . (canceled)

37 . A method of delivering a therapeutic agent or diagnostic agent to a surface, comprising contacting the surface with the organogel of claim 1 .

38 . The method of claim 37 , wherein the surface is the skin of a subject.

39 . (canceled)

40 . A method of treating a disease or disorder, comprising administering to a subject in need thereof an effective amount of the organogel of any of claim 1 , wherein the least one therapeutic agent or diagnostic agent is released from the organogel to the subject.

Assignees

• Massachusetts Inst Technology
• Tibet Cheezheng Tibetan Medicine Co Ltd

Inventors

• Zhao Xuanhe
• Liu Xinyue
• Chen Xiaoyu
• Wang Weibo

Classifications

• A61K9/06 Primary

  Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} · CPC title

• A61K47/34 Primary

  Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence) · CPC title

• A61K31/538

  ortho- or peri-condensed with carbocyclic ring systems · CPC title

• A61K31/09

  having two or more such linkages · CPC title

• A61K9/0014

  Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00) · CPC title